Sign in Subscribe
Drugs

DuPont and Lynx Therapeutics Announce Research Collaboration on Crop Improvement

Strategic Insights

— 1 min read

DuPont and Lynx Therapeutics have entered into a research collaboration to develop new crop varieties and crop protection products. The five-year collaboration, worth up to $60 million, will provide DuPont with exclusive access to Lynx's technologies for the study of corn, soybeans, wheat, and rice. This partnership aims to leverage Lynx's advanced technologies to accelerate gene discovery and breeding programs, ultimately leading to improved crop yields and quality traits.

Key Takeaways:

  • The collaboration will provide DuPont with exclusive access to Lynx's technologies for the study of corn, soybeans, wheat, and rice, with a financial value of up to $60 million over a five-year period.
  • The partnership will leverage Lynx's bead-based technologies to enable the parallel manipulation and analysis of large libraries of cDNA or genomic DNA molecules or fragments.
  • Up to two million genes can be simultaneously handled with the Lynx parallel clone sorting technology, allowing for the discovery of genes for yield enhancement, agronomic traits, and quality traits.
  • The collaboration will enable DuPont to isolate genes that would otherwise be inaccessible with current technologies, further enhancing the company's life sciences direction.
  • The partnership will accelerate DuPont's gene discovery and breeding programs, enabling the company to maintain its competitive lead in developing quality traits that enhance product value.
  • The collaboration will benefit from improved efficiencies due to the use of a single, integrated technology platform for both gene discovery and genetic mapping.

Statistics:

  • The collaboration is worth up to $60 million over a five-year period.
  • DuPont has 83,000 employees and operates in about 70 countries.
  • Lynx Therapeutics has developed bead-based technologies that enable the parallel manipulation and analysis of large libraries of cDNA or genomic DNA molecules or fragments.
  • Up to two million genes can be simultaneously handled with the Lynx parallel clone sorting technology.
  • The partnership aims to develop new crop varieties and crop protection products.

Sources:

  • PRNewswire, "DuPont and Lynx Therapeutics Announce Research Collaboration on Crop Improvement" (November 5)
  • DuPont Annual Report, 2002
  • Lynx Therapeutics, "About Lynx"

Read more